About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Antibiotic 'Erythromycin' Aids Treatment of Respiratory Disorder: Study

by Rukmani Krishna on March 29, 2013 at 10:54 PM
Font : A-A+

 Antibiotic 'Erythromycin' Aids Treatment of Respiratory Disorder: Study

According to a study, among patients with the lung disorder non-cystic fibrosis bronchiectasis, treatment with the antibiotic erythromycin resulted in improvement in symptoms but also increased the risk of antibiotic resistance. The study appeared in the March 27 issue of JAMA.

David J. Serisier, M.B.B.S., D.M., F.R.A.C.P., of Mater Adult Hospital, South Brisbane, Australia, and colleagues tested the hypothesis that low-dose erythromycin would reduce pulmonary exacerbations in patients with non-CF bronchiectasis with a history of frequent exacerbations.

Advertisement

The study consisted of a 12-month randomized controlled trial of erythromycin in currently nonsmoking, adult patients with non-CF bronchiectasis with a history of 2 or more infective exacerbations in the preceding year. The study was undertaken between October 2008 and December 2011 in a university teaching hospital. Patients received twice-daily erythromycin ethylsuccinate (400 mg) or matching placebo. The primary measured outcome was the annualized average rate of protocol-defined pulmonary exacerbations (PDPEs) per patient. Secondary outcomes included macrolide resistance and lung function.

Six-hundred seventy-nine patients were screened, 117 were randomized (58 placebo, 59 erythromycin), and 107 (91.5 percent) completed the study. The researchers found that erythromycin significantly reduced PDPEs (76 for the erythromycin group vs. 114 for the placebo group; average 1.29 vs. 1.97 respectively, per patient per year). The number of patients treated with erythromycin who had zero PDPEs was 20 (vs. 16 for placebo), and 10 patients had more than 2 PDPEs (vs. 18, respectively).
Advertisement

Erythromycin also reduced PDPEs in the prespecified subgroup with baseline Pseudomonas aeruginosa airway infection. In addition, there were significantly fewer total respiratory events (total PDPEs plus non-PDPEs) in the erythromycin group (111 vs. 176 for placebo; average, 1.88 vs. 3.03 per patient per year).

"Erythromycin reduced 24-hour sputum production and attenuated [lessened] lung function decline compared with placebo. Erythromycin increased the proportion of macrolide-resistant oropharyngeal streptococci," the authors write.

"In conclusion, long-term low-dose erythromycin significantly reduced exacerbations, protected against lung function decline, reduced sputum production, and significantly increased macrolide resistance in oropharyngeal streptococci. The bacterial resistance caused by macrolide therapy mandates a cautious application of this therapy in clinical practice. Further studies are needed to evaluate the possibility that P aerugmosa-infected individuals with frequent exacerbations may represent an appropriate subgroup for limitation of this therapy."

Source: Eurekalert
Advertisement

Advertisement
Advertisement

Recommended Reading

Latest Respiratory Disease News

 Artificial Intelligence-enabled Chest Scan Improves Pulmonary Hypertension Diagnosis
A new artificial intelligence-enabled chest imaging technology performs a deep characterization of the pulmonary vasculature to detect pulmonary (arterial) hypertension.
Could a Severe Heatwave Lead to Asthma?
The global climate crisis is stimulating heat waves to become more frequent causing distress to people with asthma, say experts.
Why Is Vitamin D3 Essential for Allergic Asthma?
A new study reveals vitamin D3 supplements have encouraging effects for asthma patients. Vitamin D has a positive effect on immune response.
Why Are First Nations Population at Risk of Severe Flu?
Hospitalization and mortality rates are on the higher side in First Nations communities than comparable populations.
Ending Tobacco Use: A Blueprint Towards Eradicating Tuberculosis
To end TB by 2030, we need to decrease tuberculosis risk factors and reduce NCDs, among other vital steps to strengthen health systems.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Antibiotic 'Erythromycin' Aids Treatment of Respiratory Disorder: Study Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests